Leadership in Ubiquitin Drug Discovery
Progenra’s discovery platforms are derived from the ubiquitin-proteasome system (UPS), a major regulator of cellular functions. Understanding of the key players in the enzymatic pathways of the UPS and their importance in various diseases has increased, and ubiquitin-based discovery research is quite active today. The most recent ubiquitin-related therapeutic modality – PROTAC® molecules – exploit the E3 ligase function by bringing together a ligase and an otherwise undruggable substrate to eliminate the substrate for therapeutic benefit. Progenra’s platforms address both small molecule ubiquitin pathway enzyme modulators and novel degraders such as PROTACs.
Progenra scientists and collaborators continue to develop first in class breakthrough small molecule drug candidates with in vivo proof of concept. Ubiquitin is not only a tag for protein degradation, but also a regulator of the cellular location or activity of extant proteins in ways that can be exploited therapeutically. We are continually incorporating newly uncovered roles for ubiquitin, including its role in PROTACs, into our technology.
Progenra’s biologists, medicinal chemists, and external network enable the discovery and development of clinical candidates in cancer, viral infection, cardiovascular disease, inflammation, neurodegenerative diseases, and others.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.